Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.

Sozzi G, Martelli MP, Conte D, Modena P, Pettirossi V, Pileri SA, Falini B.

Haematologica. 2009 Sep;94(9):1307-11. doi: 10.3324/haematol.2009.008045.

2.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M.

N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.

3.

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR.

Clin Cancer Res. 2009 Aug 15;15(16):5216-23. doi: 10.1158/1078-0432.CCR-09-0802. Epub 2009 Aug 11. Erratum in: Clin Cancer Res. 2009 Nov 15;15(22):7110.

4.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

5.

Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.

Laurent C, Do C, Gascoyne RD, Lamant L, Ysebaert L, Laurent G, Delsol G, Brousset P.

J Clin Oncol. 2009 Sep 1;27(25):4211-6. doi: 10.1200/JCO.2008.21.5020. Epub 2009 Jul 27. Erratum in: J Clin Oncol. 2010 Jan 1;28(1):182.

6.

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, Wang X, Peterson LM, Halling KC, Oliveira AM, Aubry MC, Yi ES.

Hum Pathol. 2009 Aug;40(8):1152-8. doi: 10.1016/j.humpath.2009.01.012. Epub 2009 Apr 22.

PMID:
19386350
7.

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.

Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H.

Clin Cancer Res. 2009 May 1;15(9):3143-9. doi: 10.1158/1078-0432.CCR-08-3248. Epub 2009 Apr 21.

8.

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y.

Mod Pathol. 2009 Apr;22(4):508-15. doi: 10.1038/modpathol.2009.2. Epub 2009 Feb 20.

9.

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta M, Fernández PL, Ramirez J, Chan JK, Grigioni WF, Campo E, Pileri SA, Falini B.

Am J Pathol. 2009 Feb;174(2):661-70. doi: 10.2353/ajpath.2009.080755. Epub 2009 Jan 15.

10.

A mouse model for EML4-ALK-positive lung cancer.

Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y, Sugiyama Y, Mano H.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7. doi: 10.1073/pnas.0805381105. Epub 2008 Dec 8.

11.

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H.

Clin Cancer Res. 2008 Oct 15;14(20):6618-24. doi: 10.1158/1078-0432.CCR-08-1018.

12.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA.

Clin Cancer Res. 2008 Jul 1;14(13):4275-83. doi: 10.1158/1078-0432.CCR-08-0168.

13.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

14.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ.

Cell. 2007 Dec 14;131(6):1190-203.

15.

Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Alberg AJ, Ford JG, Samet JM; American College of Chest Physicians.

Chest. 2007 Sep;132(3 Suppl):29S-55S. Review.

PMID:
17873159
16.

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.

Sequist LV, Lynch TJ.

Annu Rev Med. 2008;59:429-42. Review.

PMID:
17716025
17.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11.

PMID:
17625570
18.

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Sequist LV, Bell DW, Lynch TJ, Haber DA.

J Clin Oncol. 2007 Feb 10;25(5):587-95. Review.

PMID:
17290067
19.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.

Science. 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29.

20.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

Items per page

Supplemental Content

Write to the Help Desk